Get the Stockscreener App
1.31
0.77%
0.01
Redhill Biopharma Ltd Adr stock is traded at $1.31, with a volume of 32,543.
It is up +0.77% in the last 24 hours and down -39.63% over the past month.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
See More
Previous Close:
$1.30
Open:
$1.29
24h Volume:
32,543
Relative Volume:
0.07
Market Cap:
$3.01M
Revenue:
$35.75M
Net Income/Loss:
$11.57M
P/E Ratio:
-0.3441
EPS:
-3.8069
Net Cash Flow:
$-26.25M
1W Performance:
-3.68%
1M Performance:
-39.63%
6M Performance:
-72.48%
1Y Performance:
-86.25%
1-Day Range:
$1.275
$1.36
1-Week Range:
$1.275
$1.48
52-Week Range:
$1.06
$12.50
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Compare RDHL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
1.31 | 3.31M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-11-20 | Initiated | BTIG Research | Buy |
| Jul-12-19 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-12-19 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Jan-26-18 | Initiated | Nomura | Buy |
| Oct-06-17 | Initiated | Seaport Global Securities | Buy |
| Oct-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-17 | Reiterated | FBR & Co. | Outperform |
| Jul-27-16 | Reiterated | FBR Capital | Outperform |
| Sep-29-15 | Initiated | Nomura | Buy |
| Jul-29-15 | Reiterated | ROTH Capital | Buy |
| Jun-17-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-15 | Reiterated | ROTH Capital | Buy |
View All
Redhill Biopharma Ltd Adr Stock (RDHL) Latest News
RedHill Biopharma receives Nasdaq extension to regain compliance by October - Investing.com South Africa
Redhill Biopharma stock soars after FDA provides positive pathway for Crohn’s drug - Investing.com India
Taking the lead: Redhill Biopharma Ltd. ADR (RDHL) - Sete News
The time has not yet come to remove your chips from the table: Hertz Global Holdings Inc (HTZ) - Sete News
A significant driver of top-line growth: Alexandria Real Estate Equities Inc (ARE) - Sete News
Redhill Biopharma Ltd. ADR [RDHL] Insider Activity: An Update for Investors - knoxdaily.com
RedHill Biopharma faces Nasdaq non-compliance issue - Investing.com
RedHill Biopharma faces Nasdaq non-compliance issue By Investing.com - Investing.com India
Redhill Biopharma stock hits 52-week low at $1.72 amid market challenges - Investing.com
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com India
RedHill Biopharma targets UK approval for H. pylori therapy By Investing.com - Investing.com South Africa
Redhill Biopharma Ltd. ADR (RDHL)’s Stock Price Falls Due To Weak Fundamental Momentum - Marketing Sentinel
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline By Investing.com - Investing.com South Africa
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
What Did We Note About Insider Trading At Redhill Biopharma Ltd. ADR (NASDAQ: RDHL)? - Stocks Register
Hyloris secures global rights to RedHill’s RHB-102 - Investing.com India
Redhill Biopharma stock hits 52-week low at $4.79 - Investing.com India
Earnings call transcript: RedHill Biopharma Q1 2022 sees revenue dip - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com
RedHill stock rises on expanded Medicare coverage By Investing.com - Investing.com South Africa
RedHill wins $8 million judgment in New York court - Investing.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR.com
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - Barchart.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds - Barchart.com
RedHill Biopharma to Implement ADS Ratio Change to 1:400 By Investing.com - Investing.com India
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment - PR Newswire UK
Cathie Wood Predictions 2022 - New Trader U
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
RedHill Biopharma files for further Nasdaq offering - גלובס
Redhill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
Redhill Biopharma Ltd Adr Stock (RDHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):